|
Liver Cirrhosis, Experimental
|
0.500 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Liver Cirrhosis, Experimental
|
0.500 |
Biomarker
|
disease |
RGD |
Altered CD38 expression in thioacetamide-induced rat model of liver cirrhosis.
|
16343077 |
2005 |
|
Myocardial Ischemia
|
0.500 |
Biomarker
|
disease |
CTD_human |
Cardioplegia prevents ischemia-induced transcriptional alterations of cytoprotective genes in rat hearts: a DNA microarray study.
|
16214533 |
2005 |
|
Myocardial Ischemia
|
0.500 |
Biomarker
|
disease |
RGD |
Myocardial ischemia and reperfusion reduce the levels of cyclic ADP-ribose in rat myocardium.
|
12111041 |
2002 |
|
Albuminuria
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
This enhanced glomerular injury in CD38(-/-) or CD38-shRNA mice was accompanied by increased albuminuria and proteinuria.
|
21992601 |
2012 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.240 |
Biomarker
|
disease |
BEFREE |
The clinical phenotype of anti-CD38-positive Type 2 diabetes differs from the LADA (latent autoimmune diabetes of adults) phenotype.
|
15505998 |
2005 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.240 |
Biomarker
|
disease |
BEFREE |
Autoimmunity to CD38 and GAD in Type I and Type II diabetes: CD38 and HLA genotypes and clinical phenotypes.
|
12242463 |
2002 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.240 |
GeneticVariation
|
disease |
BEFREE |
Autoantibody response to CD38 in Caucasian patients with type 1 and type 2 diabetes: immunological and genetic characterization.
|
11289039 |
2001 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.240 |
GeneticVariation
|
disease |
BEFREE |
The Arg140Trp mutation on CD38 thus appears to contribute to the development of Type II diabetes mellitus via the impairment of glucose-induced insulin secretion in the presence of other genetic defects.
|
9754820 |
1998 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.240 |
Biomarker
|
disease |
RGD |
Expression of CD38 gene, but not of mitochondrial glycerol-3-phosphate dehydrogenase gene, is impaired in pancreatic islets of GK rats.
|
7669044 |
1995 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.220 |
AlteredExpression
|
disease |
BEFREE |
We utilized surface expression of CD38 on newly activated CD4 memory T cells as a strategy to identify type 1 diabetes associated autoreactive T cells activated by influenza vaccination in healthy subjects.
|
30619245 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.220 |
Biomarker
|
disease |
MGD |
Targeted disruption of CD38 accelerates autoimmune diabetes in NOD/Lt mice by enhancing autoimmunity in an ADP-ribosyltransferase 2-dependent fashion.
|
16585549 |
2006 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.220 |
Biomarker
|
disease |
BEFREE |
Recently, the presence of CD38 autoantibodies has been found in a significant number (9-15%) of patients with Type 2 or long-standing Type 1 diabetes.
|
15505998 |
2005 |
|
Diabetic Nephropathy
|
0.200 |
Biomarker
|
disease |
RGD |
Role of kidney ADP-ribosyl cyclase in diabetic nephropathy.
|
19073639 |
2009 |
|
Cardiomegaly
|
0.200 |
Biomarker
|
phenotype |
RGD |
Inhibition of ADP-ribosyl cyclase attenuates angiotensin II-induced cardiac hypertrophy.
|
18719074 |
2009 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, Daratumumab is a human IgG1κ monoclonal antibody targeting CD38 and is used to treat multiple myeloma.
|
31693245 |
2020 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
VS38 is a viable alternative to bright CD38 to identify plasma cells and particularly helpful in myeloma cases with dim CD38 and after daratumumab.
|
31679012 |
2020 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The model is validated with clinical data from the anti-FcRn antibody M281 and is used to conduct a scenario test to quantify the interaction among M-protein, the characteristic paraprotein of multiple myeloma (MM), and the anti-CD38 antibody daratumumab indicated for MM treatment.
|
31449666 |
2020 |
|
refractory multiple myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Daratumumab (DARA) is a humanized Immunoglobulin G(IgG)1-kappa monoclonal antibody against CD38 antigen that is shown to improve outcomes in relapsed/refractory plasma cell myeloma (PCM) patients.
|
31313879 |
2020 |
|
refractory multiple myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The anti-CD38 antibody daratumumab is approved for treatment of refractory multiple myeloma and acts by depletion of plasma cells and modification of various T-cell functions.
|
31630242 |
2020 |
|
refractory multiple myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pretreatment CD38-positive regulatory T-cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients.
|
31004032 |
2020 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Anti-CD38 mAbs-mediated PC depletion in autoimmunity and organ transplants is currently under investigation.
|
31783629 |
2019 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, these data indicate that depletion of CD38-expressing cells could be a therapeutic mechanism for treating autoimmune diseases.
|
31085699 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Based on the high activity and favorable toxicity profile of daratumumab, other CD38 antibodies, such as isatuximab, MOR202, and TAK-079, are being evaluated in MM and other malignancies.
|
30826127 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Anti-CD38/CD3 XmAb T-cell-recruiting antibodies with different affinities for CD38 and CD3 were assessed <i>in vitro</i> and <i>in vivo</i> for their redirected T-cell lysis activity against cancer cell lines, their lower levels of cytokine release, and their potency in the presence of high levels of soluble CD38.
|
30918018 |
2019 |